Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhinase Lubricating Nasal Mist is an over-the-counter (OTC) intranasal spray developed and marketed by Profounda Inc. for the management of nasal dryness and irritation. The formulation is a steroid-free, aloe-free, hypotonic solution with a pH of 6.2, designed to match the natural environment of the nasal cavity. It contains two wetting agents—polyethylene glycol (15%) and propylene glycol (5%)—along with sodium chloride and potassium chloride. These ingredients work synergistically to hydrate the nasal mucosa and dissolve thick or crusty mucus. Rhinase is indicated for dryness resulting from various conditions, including allergies, chronic sinusitis, low humidity, nosebleeds, and the use of medical devices such as CPAP machines or oxygen therapy. It was launched in 2016 as a US-manufactured reformulation of the Canadian product Rhinaris.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rhinase Lubricating Nasal Mist.